CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01556815
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:20.198979+00:00
Published At: 2012-04-25T00:00:00+00:00
Record Updated At: 2012-04-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["PHENYTOIN/SORAFENIB [VA Drug Interaction]", "Liver Neoplasms", "Carcinoma, Hepatocellular", "Digestive System Neoplasms", "Neoplasms by Site", "Liver Diseases", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]", "HBV"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-04-25"
protocolSection.identificationModule.nctId: "NCT01556815"
protocolSection.identificationModule.officialTitle: "Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.